The U.S. Tax Court ruled that a pharmaceutical corporation’s FASIT arrangement was invalid because the Series A/E Stock didn’t meet the regular interest requirements, thereby upholding the IRS’s deficiency determination. ...
U.S. Tax Court Invalidates Taxpayer’s FASIT Arrangement, Upholds IRS Deficiency Determination
